Clinical Pharmacokinetics of 1-[((S)-2-Hydroxy-2-Oxo-1,4,2-Dioxaphosphorinan-5-yl)methyl]cytosine in Human Immunodeficiency Virus-Infected Patients

Documenti analoghi

• 1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl] cytosine, an intracellular prodrug for (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine with improved therapeutic index in vivo.
  di: Bischofberger, N, et al.
  Pubblicazione: (1994)
• Conversion of 1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl]cytosine to cidofovir by an intracellular cyclic CMP phosphodiesterase.
  di: Mendel, D B, et al.
  Pubblicazione: (1997)
• Selective Inhibition of Human Papillomavirus-Induced Cell Proliferation by (S)-1-[3-Hydroxy-2-(Phosphonylmethoxy)propyl]cytosine
  di: Johnson, J. A., et al.
  Pubblicazione: (1999)
• Safety, Pharmacokinetics, and Antiretroviral Activity of Intravenous 9-[2-(R)-(Phosphonomethoxy)propyl]adenine, a Novel Anti-Human Immunodeficiency Virus (HIV) Therapy, in HIV-Infected Adults
  di: Deeks, Steven G., et al.
  Pubblicazione: (1998)
• Inhibition of acetylcholinesterase by derivatives of 1,3,2-dioxaphosphorinane 2-oxide.
  di: Coult, D B
  Pubblicazione: (1976)